If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
63
results.
Updated on
28/10/2026 [06:45:00]
Results 25 to 50 of 63
Absstract of: AU2025235980A1
Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
Absstract of: US20260311880A1
0000 Disclosed are methods of monitoring minimum residual disease using genomic profiling. In some methods, a subject has or has had multiple myeloma or a precursor thereof. The methods include amplifying a sample using primary template-directed whole genome amplification (PTWGA) and enable monitoring of liquid samples, such as blood samples.
Absstract of: WO2026210100A1
The invention relates to a method for the in vitro diagnosis of a B-cell lymphoma of the central nervous system, comprising analysing the methylation status of at least one, in particular of at least two, more particularly of at least three, preferably of at least four, more preferably of the five CpG motifs of the LRP5 (Low-density lipoprotein receptor-related protein 5) gene present in the circulating free DNA derived from at least one cerebrospinal fluid sample. The invention also relates to a method for monitoring the response to an anti-cancer treatment and to kits associated with the method for in vitro diagnosis.
Absstract of: WO2026213527A1
The present invention provides methods and compositions for using a piperidinyl-methylpurineamine nuclear SET domain- containing protein 2 (NSD2) inhibitor to treat light chain myeloma in subjects with reduced activity of the TP53 gene or elevated expression of NSD2 due to a medical defect other than a t(4; 14) translocation.
Absstract of: WO2026213556A1
The present disclosure is concerned with pharmaceutical compositions comprising an inosine-5' -monophosphate dehydrogenase 2 (IMPDH2) inhibitor and methods of treating cancer (e.g., a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Absstract of: WO2026213197A1
The present invention relates to lH-pyrazolo3,4-bpyridine compounds and methods useful as inhibitors of HRI kinase for the treatment or prevention of hematological disorders The invention includes a method of treating myelodysplastic syndrome in patients who are non-responders to luspatercept or elythropoiesis-stimulating agents comprising the administration, to a patient in need thereof, of a HRI kinase inhibitor.
Absstract of: US20260308226A1
The present invention provides NK cell compositions and/or preparations and methods of using such NK cell compositions and/or preparations for immunotherapy. The NK cell compositions and/or preparations can be used in therapies of a broad range of viral infections, bacterial infections, cancer and leukemia malignancies, and other diseases.
Absstract of: US20260308130A1
0000 A genus of bicyclic inhibitors of CBX chromodomains is disclosed. The compounds are of the following genus:
0000
0000 The compounds inhibit CBX proteins and, as a consequence, they are useful for treating prostate cancer, ovarian cancer, and B-cell lymphoma.
Absstract of: US20260308148A1
The present application relates to a sulfur-containing isoindoline derivative, and a preparation method therefor and medical use thereof. In particular, the present disclosure relates to a sulfur-containing isoindoline derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and use thereof as a therapeutic agent, particularly use thereof as a Cereblon modulator in the field of treatment of multiple myeloma.
Absstract of: US20260308696A1
The present invention includes methods for treating a human patient with Crenolanib, wherein the human patient is suffering from a FLT3 mutated leukemia, the method comprising: determining that the human patient has a poor prognosis by: obtaining or having obtained a leukemia biological sample and performing or having performed a genotyping assay on the biological sample to determine that the human patient has both a mutated FLT3 or a constitutively active FLT3 mutant and one or more driver mutations in one or more epigenetic regulator proteins that results in a loss of normal function of the epigenetic regulator proteins which, indicates that the patient has a poor prognosis; and administering to the patient determined to have the poor prognosis a therapeutically effective amount of Crenolanib, or a pharmaceutically acceptable salt thereof having the formula:to treat the leukemia.
Absstract of: US20260308116A1
0000 Tertiary amine compounds that have an alkyne group or an azide group, in particular an alkyne group, and/or their pharmaceutically acceptable salts and solvates that are useful to monitor DNA lesions and to reveal interstrand crosslinks repair defects are disclosed herein. Methods of monitoring DNA lesions in patients selected from Fanconi Anemia (FA) patients, xeroderma pigmentosum (XP) patients, acute myeloid leukemia (AML) patients, head-and-neck cancer patients, ovarian cancer patients, and breast cancer patients using the tertiary amine compounds and/or their pharmaceutically acceptable salts and solvates are also disclosed.
Absstract of: US20260308690A1
0000 A 139-gene epigenetic signature for use in. methods for assessing the age and longevity of a T cell, selecting a T cell for a T cell therapy, and/or determining a T-cell acute lymphoblastic leukemia subtype is provided.
Absstract of: US20260308541A1
0000 The present invention relates to reverse transcriptase enzymes comprising a modified Moloney Murine Leukaemia Virus reverse transcriptase amino acid sequence, wherein said amino acid sequence comprises a mutation compared to the wild-type Moloney Murine Leukaemia Virus reverse transcriptase, and said enzyme possesses increased inhibitor resistance compared to the wild-type Moloney Murine Leukaemia Virus reverse transcriptase. The present invention also relates to compositions, reaction mixtures, and kits comprising the said reverse transcriptase enzymes are used to synthesize cDNA from RNA.
Absstract of: US20250177520A1
Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.
Absstract of: GB2705174A
A chimeric protein comprising a first peptide and first and second segments of a second peptide. The second peptide includes an epitope. The N-terminus of the first peptide is linked to either the first or the second segment of the second peptide. The C-terminus of the first peptide is linked to the other of the first or second segment of the second peptide. The epitope can be formed from both segments of the second peptide. The second peptide can be IL-31, IL-6, IL-11, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine (CLC), or IL-27. The second peptide can be human or canine IL-31. The first peptide can be a bacterial colicin, bacterial ribonuclease, spycatcher protein, ColE7, or Barnase. The second peptide can be divided into the first and second segments at a division site from an unstructured region or a glycine residue. A further aspect is a virus-like particle comprising the chimeric protein. A further aspect is a polynucleotide capable of hybridizing the polynucleotide. A further aspect is an immunogenic composition comprising the chimeric protein for use in treating atopic dermatitis, cancer, inflammatory, neurodegenerative, metabolic, cardiovascular, renal, gastrointestinal, respiratory, autoimmune diseases. Figure 5
Absstract of: GB2705211A
A chimeric protein comprising a first peptide linked to a second peptide. The second peptide includes an epitope. The second peptide is formed from C-terminal and N-terminal segments of a target peptide comprising the epitope. The relative positions of the C-terminal segment and the N-terminal segment are transposed in the second peptide relative to the target peptide. The epitope can be formed from both first and second segments of the second peptide. The second peptide can be IL-31, IL-6, IL-11, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine (CLC), or IL-27. The second peptide can be human or canine IL-31. The first peptide can be a bacterial colicin, bacterial ribonuclease, spycatcher protein, ColE7, or Barnase. A further aspect is a virus-like particle comprising the chimeric protein. A further aspect is a polynucleotide capable of hybridizing the polynucleotide. A further aspect is a method of producing the chimeric protein wherein the target peptide is split at a division site without disrupting formation of secondary structure elements. A further aspect is an immunogenic composition comprising the chimeric protein for use in treating atopic dermatitis, cancer, inflammatory, neurodegenerative, metabolic, cardiovascular, renal, gastrointestinal, respiratory, autoimmune diseases. Figure 6
Absstract of: EP4817602A1
The present invention provides an EGFR inhibitor for use in the preparation of a medicament for treating diseases mediated by guanosine exchange factor (GEF) activity or co-mediated by guanosine nucleotide exchange factor (GEF) activity and EGFR tyrosine kinase activity, wherein the diseases are selected from the group consisting of: lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, melanoma, leukemia, and glioblastoma. Specifically, the present invention has discovered that in addition to its conventional tyrosine kinase activity, EGFR also possesses a GEF function that promotes the activation of Ras homologous protein (Rheb), this function is independent of its tyrosine kinase activity and relies critically on the glutamate residue at position 804 on the EGFR molecule. The Rheb-GEF activity of EGFR induces allosteric activation of mammalian target of rapamycin complex 1 (mTORC1), ultimately promoting tumor growth.
Absstract of: EP4818207A1
0001 The present invention relates to a recombinant polypeptide that specifically binds to B lymphocytes and a composition for preventing or treating B-cell lymphoma, comprising the recombinant polypeptide as an active ingredient. The present invention can significantly enhance direct cell death activity against tumor cells by conjugating concanavalin A, a ligand of MPZL1, to an antibody molecule that recognizes a B-lymphocyte-specific antigen such as CD20. Accordingly, unlike therapeutic antibodies that act mainly through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADP), the recombinant polypeptide of the present invention does not depend on effector mechanisms of a patient's immune system. Therefore, the recombinant polypeptide can be usefully employed as an effective therapeutic composition even for cancer patients with reduced immune activity.
Absstract of: EP4818333A1
The present invention relates to an in vitro method for detecting multiple myeloma in a subject. The invention further provides the use of chemokine receptor CXCR3 (CXCR3) as a biomarker for diagnosing, prognosing, and/or treatment monitoring of multiple myeloma in a subject. The invention further provides a kit for the detection of multiple myeloma in a subject.
Absstract of: NL4002684A
0001 ABSTRACT Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an 5 epitope of BCMA are administered to the subject.
Absstract of: MX2026001573A
Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and/or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.
Absstract of: MX2026007480A
Some embodiments of the disclosure include compounds of Formula (I) and Formula (la), and compositions thereof, e.g., pharmaceutical compositions, which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the compounds (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Absstract of: MX2026010197A
The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
Absstract of: MX2026010514A
This application pertains to the use of Compound (A): or a pharmaceutically acceptable salt thereof, for the treatment of various diseases or disorders, including, for example, advanced non-Hodgkin lymphoma (NHL), relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), transformed follicular lymphoma, nodal T-follicular helper cell lymphoma (nTFHL), relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma, nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL- Al) / advanced angioimmunoblastic T-cell lymphoma (AITL), or relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL-AI) / angioimmunoblastic T-cell lymphoma (AITL).
Nº publicación: WO2026202706A1 01/10/2026
Applicant:
DANA FARBER CANCER INST INC [US]
DANA-FARBER CANCER INSTITUTE, INC.
Absstract of: WO2026202706A1
The present invention provides compounds of Formula I:, I which are useful for the inhibition of KAT6A, KAT6B, and/or KAT7. Compounds of Formula I are useful for the treatment of cancer, including bladder cancer, breast cancer, cervical cancer, colorectal cancer including colon and rectal adenocarcinomas, leukemias including acute myeloid leukemia (AML), lung adenocarcinoma, medulloblastoma, osteosarcoma, ovarian cancer, and prostate cancer.
BOPI
Electronic site
